---
title: "Key facts: Eli Lilly posts $23B quarter; Foundayo approved, $50 copay"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302954987.md"
description: "Eli Lilly reported $23B quarterly revenue, up 48% YoY, driven by Mounjaro and Zepbound sales. The company secured April 2026 approval for its oral GLP-1 therapy, Foundayo, which is subject to Medicare's new $50 copay policy. Additionally, Phase 1 data for an ovarian cancer ADC showed strong efficacy. Shares fell 1.7% premarket ahead of earnings as investors assessed pricing impacts."
datetime: "2026-10-24T07:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302954987.md)
  - [en](https://longbridge.com/en/news/302954987.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302954987.md)
generator: "portal-rs"
---

# Key facts: Eli Lilly posts $23B quarter; Foundayo approved, $50 copay

-   Eli Lilly (LLY) posted $23.0B quarterly revenue, up 48% year-over-year. Volumes rose 60% while realized prices fell 13%. Mounjaro and Zepbound drove about $14.9B of sales. GuruFocus
-   Eli Lilly (LLY) won April 2026 approval for Foundayo, its oral GLP‑1 therapy, marking market authorization for the company’s oral GLP‑1 product. Benzinga
-   Medicare’s 2025 policy sets a $50 copay for approved injectable and oral GLP-1s. Eli Lilly’s oral GLP-1 Foundayo is included among drugs subject to the $50 copay. Benzinga
-   Eli Lilly (LLY) reported Phase 1 ESMO 2026 data for its FRα-targeting ADC in platinum-sensitive ovarian cancer: objective response rate 79%, disease control rate 100%. Reuters
-   Eli Lilly (LLY) GLP‑1 drug Mounjaro linked to higher consumer demand for high‑protein foods; surveys show users plan about 11% higher spending to offset potential GLP‑1–related muscle loss Reuters
-   Eli Lilly (LLY) shares fell about 1.7% in premarket trading ahead of its earnings release as traders positioned for results and pricing impact on profit. GuruFocus

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)

## Related News & Research

- [Eli Lilly and Company $LLY Shares Sold by USAdvisors Wealth Management LLC](https://longbridge.com/en/news/302964762.md)
- [Eli Lilly and Company $LLY Shares Sold by Essential Planning LLC.](https://longbridge.com/en/news/302956671.md)
- [Eli Lilly and Co Stock (LLY) Opened Up by 5.01% on Oct 20: A Full Analysis](https://longbridge.com/en/news/302432875.md)
- [Correction to Eli Lilly's Omvoh Hits Goal in Phase 3 Study Article on Oct. 19](https://longbridge.com/en/news/302438751.md)
- [Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY](https://longbridge.com/en/news/302983382.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**